These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 17244255)

  • 1. Non-clinical safety studies on biosimilar recombinant human erythropoietin.
    Parnham MJ; Schindler-Horvat J; Kozlović M
    Basic Clin Pharmacol Toxicol; 2007 Feb; 100(2):73-83. PubMed ID: 17244255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Similar biological medicinal products containing recombinant human growth hormone: European regulation.
    Pavlovic M; Girardin E; Kapetanovic L; Ho K; Trouvin JH
    Horm Res; 2008; 69(1):14-21. PubMed ID: 18059081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The scope and requirements related to preclinical and clinical studies of a new medicinal product, including biotechnological and biosimilar products.
    Brodniewicz-Proba T
    Acta Pol Pharm; 2008; 65(6):641-5. PubMed ID: 19172845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the bioequivalence of biosimilars The Retacrit case.
    Schellekens H
    Drug Discov Today; 2009 May; 14(9-10):495-9. PubMed ID: 19429509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.
    Jelkmann W
    Am J Hematol; 2010 Oct; 85(10):771-80. PubMed ID: 20706990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilar medicines--new challenges for a new class of medicine.
    Fox A
    J Biopharm Stat; 2010 Jan; 20(1):3-9. PubMed ID: 20077245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilars approval process.
    Zuñiga L; Calvo B
    Regul Toxicol Pharmacol; 2010 Apr; 56(3):374-7. PubMed ID: 19925842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical assessment of biosimilar products.
    Chow SC; Liu JP
    J Biopharm Stat; 2010 Jan; 20(1):10-30. PubMed ID: 20077246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars and regulatory authorities.
    Minghetti P; Rocco P; Del Vecchio L; Locatelli F
    Nephron Clin Pract; 2011; 117(1):c1-7. PubMed ID: 20689318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Follow-on biologics: challenges of the "next generation".
    Schellekens H
    Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv31-36. PubMed ID: 15827057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European regulatory guidelines for biosimilars.
    Wiecek A; Mikhail A
    Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v17-20. PubMed ID: 16959790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biosimilar: can we manage biopharmaceutical heterogeneity?].
    Ranieri E
    G Ital Nefrol; 2008; 25(3):275. PubMed ID: 18473296
    [No Abstract]   [Full Text] [Related]  

  • 13. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concept of biosimilar products in Jordan.
    Haddadin RD
    Biologicals; 2011 Sep; 39(5):333-5. PubMed ID: 21873079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory guideline for biosimilar products in Korea.
    Suh SK; Park Y
    Biologicals; 2011 Sep; 39(5):336-8. PubMed ID: 21784653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparability and biosimilarity: considerations for the healthcare provider.
    Lee JF; Litten JB; Grampp G
    Curr Med Res Opin; 2012 Jun; 28(6):1053-8. PubMed ID: 22519391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The regulatory system in europe with special emphasis on allergen products.
    Lorenz AR; Luttkopf D; Seitz R; Vieths S
    Int Arch Allergy Immunol; 2008; 147(4):263-75. PubMed ID: 18648190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Similar biological medicinal products currently licensed in the European union--overview of non-clinical study programs.
    Heim HK
    Biologicals; 2011 Sep; 39(5):284-8. PubMed ID: 21871818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Biosimilar products--cheaper version of biological drugs. New possibilities within several therapeutic fields].
    Mellstedt H
    Lakartidningen; 2009 Jun 3-9; 106(23):1563-6. PubMed ID: 19583014
    [No Abstract]   [Full Text] [Related]  

  • 20. Recommendations regarding technical standards for follow-on biologics: comparability, similarity, interchangeability.
    Davis GC; Beals JM; Johnson C; Mayer MH; Meiklejohn BI; Mitlak BH; Roth JL; Towns JK; Veenhuizen M
    Curr Med Res Opin; 2009 Jul; 25(7):1655-61. PubMed ID: 19476407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.